David A. Siegel Leap Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.29 - $0.72 $77,749 - $193,032	-268,100 Reduced 90.73%	27,400 $9,000
Q4 2022 Feb 14, 2023	SELL	$0.42 - $9.18 $49,812 - $1.09 Million	-118,600 Reduced 28.64%	295,500 $132,000
Q3 2022 Nov 14, 2022	SELL	$0.92 - $9.3 $314,180 - $3.18 Million	-341,500 Reduced 45.2%	414,100 $364,000
Q2 2022 Aug 15, 2022	SELL	$0.96 - $1.91 $299,712 - $596,302	-312,200 Reduced 29.24%	755,600 $869,000
Q1 2022 May 16, 2022	SELL	$1.6 - $3.35 $734,080 - $1.54 Million	-458,800 Reduced 30.05%	1,067,800 $1.87 Million
Q4 2021 Feb 14, 2022	BUY	$2.08 - $3.65 $2.36 Million - $4.14 Million	1,133,800 Added 288.65%	1,526,600 $4.95 Million
Q3 2021 Nov 15, 2021	BUY	$1.35 - $4.01 $86,332 - $256,439	63,950 Added 19.45%	392,800 $1.58 Million
Q2 2021 Aug 16, 2021	SELL	$1.48 - $1.92 $465,534 - $603,936	-314,550 Reduced 48.89%	328,850 $539,000
Q1 2021 May 17, 2021	BUY	$1.82 - $3.01 $145,600 - $240,799	80,000 Added 14.2%	643,400 $1.22 Million
Q4 2020 Feb 16, 2021	SELL	$1.49 - $2.37 $2,533 - $4,029	-1,700 Reduced 0.3%	563,400 $1.27 Million
Q3 2020 Nov 16, 2020	BUY	$1.68 - $2.17 $903,504 - $1.17 Million	537,800 Added 1969.96%	565,100 $1.12 Million
Q2 2020 Aug 14, 2020	BUY	$1.39 - $2.84 $37,947 - $77,532	27,300 New	27,300 $57,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $275M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.